Literature DB >> 11390467

Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.

V Lafont1, J Liautard, J P Liautard, J Favero.   

Abstract

Human lymphocytes expressing the gammadelta TCR represent a minor T cell subpopulation found in blood. The majority of these cells express Vgamma9Vdelta2 determinants and respond to nonpeptidic phosphoantigens. Several studies have shown that, in vivo, the percentage of Vgamma9Vdelta2 T cells dramatically increases during pathological infection, leading to the hypothesis that they play an important role in the defense against pathogens. However, the specific mechanisms involved in this response remain poorly understood. It has been established that Vgamma9Vdelta2 T cells display potent cytotoxic activity against virus-infected and tumor cells, thereby resembling NK cells. In this study, we show that, upon stimulation by nonpeptidic Ags, Vgamma9Vdelta2 T cells express FcgammaRIIIA (CD16), a receptor that is constitutively expressed on NK cells. CD16 appears to be an activation Ag for Vgamma9Vdelta2 T cells. Indeed, ligation of CD16 on Vgamma9Vdelta2 T cells leads to TNF-alpha production. This TNF-alpha production, which is dependent (like that induced via the TCR-CD3 complex) on the activation of the p38 and extracellular signal-regulated kinase-2 mitogen-activated protein kinases, can be modulated by CD94 NK receptors. Therefore, it appears that Vgamma9Vdelta2 T cells can be physiologically activated by two sequential steps via two different cell surface Ags: the TCR-CD3 complex and the FcgammaRIIIA receptor, which are specific cell surface Ags for T lymphocytes and NK cells, respectively. This strongly suggests that, in the general scheme of the immune response, Vgamma9Vdelta2 T cells represent an important subpopulation of cells that play a key role in the defense against invading pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390467     DOI: 10.4049/jimmunol.166.12.7190

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

3.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 4.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

5.  A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas.

Authors:  Heather Minto; Kofi A Mensah; Paul R Reynolds; Eric Meffre; Kira Rubtsova; Erwin W Gelfand
Journal:  Clin Immunol       Date:  2019-01-09       Impact factor: 3.969

6.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

8.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

9.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

10.  Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.

Authors:  Alessandra Musso; Silvia Catellani; Paolo Canevali; Sara Tavella; Roberta Venè; Silvia Boero; Ivana Pierri; Marco Gobbi; Annalisa Kunkl; Jean-Louis Ravetti; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.